Orphan Drugs in Asia: What you need to know

In Market Access, Orphan Drugs Live by Cameron

With the global orphan drugs market set to rise to $127 billion in the next 4 years, many expect to see a surge in orphan drug sales and development in the Asia-Pacific region.

With this in mind, we’ve put together a few graphics, with the help of Gary Pasternack CEO of Asklepion Pharmaceuticals, in order to shed a little light on this fast growing market for orphan drugs.


With a population vastly larger than that of the US and Europe, the potential market for orphan drugs is huge.

And with the possibility of much larger numbers of rare disease patients, developers could well see an increase in value for money when offset against development costs.

| Next >